The Compound Being Sold As A Way Off 7-OH Is A Synthetic Opioid That Has Never Been Tested In A Human

Update, August 25, 2026. This article was reported and checked on August 6, and the dated statements below reflect the record as it stood then. A further check of the Federal Register on August 25 confirms the temporary scheduling order covering SR-17018 still has not been published, so it remains an uncontrolled substance. Separately, the DEA has issued a temporary scheduling order placing mitragynine pseudoindoxyl, MGM-15 and MGM-16 in Schedule I, effective on publication in the Federal Register on August 26, 2026; those substances are described below as proposed. See our report on the order.

As concentrated 7-hydroxymitragynine products disappear from shelves ahead of a federal scheduling order, a different compound is being marketed to the people who were using them. It is sold online as "SR-17," in tablets, powders and solutions, by vendors who describe it as a research chemical and price it between roughly thirty and one hundred dollars.

It is not kratom. It is not derived from kratom, and it shares no structural relationship with the alkaloids in the leaf. It is a fully synthetic opioid, and the Drug Enforcement Administration moved on July 1, 2026 to place it in Schedule I, on the finding that it produces physical dependence.

What It Actually Is

"SR-17" is shorthand for SR-17018, a compound first reported in 2017 by the laboratory of Laura Bohn at Scripps Research in Florida. Its chemical name is 5,6-dichloro-1-(1-(4-chlorobenzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one, and it carries CAS number 2134602-45-0.

Structurally it is a benzimidazolone. That places it in the same chemical family as brorphine, a synthetic opioid that appeared in the illicit drug supply in 2020, and the DEA's own name for the compound reflects this: it refers to SR-17018 as 5,6-dichloro desmethylchlorphine. The mitragynine and 7-hydroxymitragynine found in Mitragyna speciosa are indole alkaloids. The two families are not related, and no synthetic step connects them.

What the compound targets is the mu-opioid receptor, the same receptor morphine acts on. Exactly how it engages that receptor is genuinely unsettled in the scientific literature. Bohn's laboratory describes it as a G-protein-biased agonist. A 2020 paper by Gillis and colleagues in Science Signaling argued instead that it is simply a low-intrinsic-efficacy partial agonist displaying "apparent bias," and Bohn's group published a direct rebuttal the following year. A 2024 paper by Singleton and colleagues proposed a third reading, that it binds outside the classical orthosteric site. That disagreement remains open. What no one in the field disputes is the receptor itself.

The Patent Trail Runs To A Public University

The compound is covered by US Patent 10,751,335 B2, "Signaling-biased mu opioid receptor agonists," granted August 25, 2020 on a priority date of March 15, 2016. The named inventors are Thomas D. Bannister, Laura M. Bohn and Cullen L. Schmid. The original assignee was The Scripps Research Institute.

The current assignee, per the patent record, is the University of Florida Research Foundation, Inc. The assignment history shows the transfer moving from Scripps in July 2020 to the University of Florida Board of Trustees and the Research Foundation in August 2022, with a corrective assignment to the Research Foundation that December.

The reason is institutional rather than commercial. Scripps Florida was absorbed by the University of Florida and now operates as The Herbert Wertheim UF Scripps Institute, where Bohn is Professor and Chair of Molecular Medicine. The patent did not change hands between rivals; the institution holding it changed names.

Two points of precision matter here. The lab code "SR-17018" does not appear in the patent text, because patents claim chemical structures rather than laboratory designations — the accurate statement is that the Research Foundation holds a patent covering this class of compounds. And nothing in the record indicates that the University of Florida, the Research Foundation, or any of the named inventors has licensed the compound to any of the vendors now selling it, or has any relationship with them whatsoever. The Kratom Council found no evidence of any such connection and is not suggesting one.

What the patent holder intends to do about any of this is not on the public record. This publication searched patent dockets, federal case law and news coverage and found no filed litigation by a university or research institution against sellers of this compound. That is a narrow finding rather than a broad one: patent holders ordinarily begin with private demand letters, which leave no docket entry and become public only if a recipient discloses one. No inference should be drawn in either direction from the absence of a court filing.

What The DEA Found

On July 1, 2026 — the same day it announced the 7-OH action — the DEA published a separate notice of intent in the Federal Register proposing to place four synthetic opioids into Schedule I: 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine and spirochlorphine.

The notice states its pharmacological finding directly:

"Available data on 5,6-dichloro brorphine and 5,6-dichloro desmethylchlorphine indicate that these two substances produce dose-dependent antinociception, reward-associated behavior, and physical dependence."

It also records what the agency has observed about how the compound is being used:

"Users also specifically report self-administering 5,6-dichloro desmethylchlorphine to reduce or reset opioid tolerance in an attempt to continue or maximize drug-induced euphoric effects."

Two clarifications about the scope of that notice, both of which have been reported carelessly elsewhere. First, as of this writing the temporary scheduling order has not been published. A check of the Federal Register on August 6 returns the July 1 notice of intent and nothing further — like the 7-OH action, this remains a proposal, and SR-17018 is not currently a controlled substance. Second, the fatality figures circulating in coverage of this notice belong to N-propionitrile chlorphine, a different compound named in the same document. The notice associates SR-17018 itself with two law-enforcement encounters across two states since 2025, and the Center for Forensic Science Research and Education reports that it has not been identified in its toxicology casework. The hazard here is an unknown safety profile in an unregulated supply, not a confirmed body count, and saying otherwise misstates the record.

The proposal has not gone unopposed. Students for Sensible Drug Policy filed an emergency challenge on July 31, and a campaign organised under the banner of stopping the scheduling has gathered public comments. Readers tracking the docket should note a naming problem that makes it easy to miss: the DEA's paperwork does not use the term "SR-17018" at all. Anyone searching the Federal Register or news coverage for that string will find nothing, and needs to search instead for "5,6-dichloro desmethylchlorphine" or "cychlorphine."

The Sales Material Contradicts Itself, And The Literature

The vendors selling this compound occupy an unusual position. They describe the product as laboratory material not intended for people, and then tell people how to take it.

One vendor's research guide states that "SR-17018 is a research compound sold exclusively for laboratory use and is NOT intended for human consumption," and carries the further warning "FOR RESEARCH USE ONLY — Not for human or veterinary consumption, diagnostic, or therapeutic use." The same page instructs readers to "gradually reduce the SR-17018 dose by approximately 10% per day."

It goes on to assert that "SR-17018 can help manage withdrawal symptoms," that "it can occupy opioid receptors to prevent withdrawal while simultaneously allowing the body's tolerance to decrease," and that "this approach generally provides better withdrawal symptom management but slower tolerance reduction." On the question of precipitated withdrawal it says: "Based on community reports, SR-17018 has not been observed to cause precipitated withdrawal."

That last qualifier is worth dwelling on. The evidentiary basis the page offers for its central safety claim is community reports — that is, the accounts of people who bought the product. It attributes its tolerance claim to "community researchers" in the same way. For a compound that has never been administered to a human being in a registered trial, anecdote from customers is the entire evidence base being offered, and the page says so.

A second vendor site markets the compound as a "highly selective, biased kappa-opioid receptor (KOR) agonist" and tells buyers that "KOR selectivity means zero interaction with mu-opioid reward pathways."

That second description is not a matter of interpretation. It is incorrect. SR-17018 is a mu-opioid receptor agonist — the title of the patent covering it says so, the DEA notice says so, and the entire published literature on the compound says so. The claim of zero interaction with reward pathways is contradicted by the catalogue entry of Cayman Chemical, a research reagent supplier, which notes that the compound induces place preference in a conditioned place preference test in mice. Place preference is the standard rodent assay for drug reward.

The tolerance claim is subtler, and needs separating into two halves. The assertion that the compound can reduce an existing opioid tolerance does have a basis in the animal literature, discussed below. The half that goes unmentioned is what it does on its own account. A 2021 paper by Pantouli and colleagues found that in the tail-immersion assay, "repeated administration of SR-17018 produces tolerance as does morphine and oxycodone." An independent group, Kudla and colleagues, found the same year that tolerance develops, if more slowly. The absence of tolerance holds in one specific assay, the hot plate, and not across the others. A reader told that this compound lowers tolerance is not being told that it builds its own.

The Kudla paper is more pointed still, and it is the paper the DEA itself cited. Its conclusion: "Both agonists develop reward-associated behavior and physical dependence… SR agonists possess rewarding and addictive properties."

A 2023 paper by Hill and colleagues examined breathing, the mechanism by which opioid overdoses kill, and reported that "the novel opioids, oliceridine, tianeptine and SR-17018 depress respiration in male mice."

The Kernel Of Truth, And Where It Stops

There is a real finding underneath the marketing, which is what makes it persuasive.

Work from Bohn's laboratory published in 2019 by Grim and colleagues found that SR-17018 reverses established morphine tolerance in mice and suppresses morphine withdrawal. That result has been replicated independently. It is genuine science, and it is the seed from which the "gets you off opioids" pitch grew.

What it does not address is the question a person considering this compound actually needs answered: what happens when you stop taking SR-17018 itself. No study in the published literature examines spontaneous withdrawal from SR-17018. The DEA's finding of physical dependence points in an unwelcome direction, but the experiment establishing what that withdrawal looks like, how long it lasts, or how it is managed has not been run.

Nor has any experiment in humans. A search of ClinicalTrials.gov for SR-17018 returns zero studies. Every one of the roughly fifteen published papers on the compound is a rodent, cell-culture or computational study. It holds no FDA approval for any indication, and has never been administered to a human being under medical supervision in a registered trial.

The substitution being marketed, then, is one dependence-producing opioid for a second dependence-producing opioid that no person has ever taken under observation.

The Same Storefronts Sell Both

The compound is not reaching people through some separate channel. It is being sold, in several documented cases, by the same retailers that sell 7-OH.

A tablet product branded "Simple Reset SR-17" has been carried by online shops that also stock 7-OH inventory, including one whose domain is 7oh.com — where, as of August 6, the product has been withdrawn and its former page returns an error, without any notice explaining why. Its marketing describes "transition support built around SR-17018," for people "looking to reset tolerance, step away from stronger habits, or return to baseline" — on a site that simultaneously describes the product as "designed for Research Purposes Only." A second product, sold through a health-shop retailer and currently listed as out of stock, is called QUIT 7. Its product page makes no explicit therapeutic claim at all; the claim is carried entirely by the name. A third storefront, Reset4Good, states that "hundreds of consumers are using SR17 to support withdrawal from addictions and mental health challenges."

Those withdrawals are not isolated. A survey of thirteen storefronts on August 6 found a market that has visibly split in two since the DEA notice published on July 1.

On one side, the consumer-facing retailers have been backing away. Elyxr, which listed a Simple Reset SR-17 product as in stock as recently as May 29, now returns a clean error on that page and the product is absent from every one of its sitemaps. Burman's Health Shop deleted one SR-17018 product outright and moved two others to out-of-stock, renaming one of them from "Simple Reset | SR-17018 Tablets 50mg" to "Simple Reset | SR-17018, Call Into The Store If Unavailable," followed by a phone number. Two shops have closed entirely: one tells visitors that "all orders prior to cut-off have been processed," the other that "demand was significant and we ran out of stock early" while promising to return with "new products." A third site is offline altogether, its servers timing out.

One vendor took a different route. Koalaty Research kept both products on sale but issued permanent redirects that strip the compound's name out of its own URLs — "sr-17018-high-purity-substance" became simply "sr-high-purity-substance," and the products now display as "S.R. powder" and "S.R. Tablets." As recently as May 13 the same page was titled "SR-17018 99.9% Pure | Buy Research Chemical Now." Another storefront has made the same shift to the bare initials.

On the other side, several vendors are selling harder than ever. One updated its catalogue on August 6 — the day this article was checked — offering not only retail packs but a master case and a master pallet of ten thousand units. Others list powder from one gram to fifty, at prices up to $2,500. None of them posts any notice. Two still tell customers, in FAQ text left unrevised, that the compound "is not currently scheduled by the U.S. DEA" — which remains technically true only because the order has not yet issued.

Read together, these are not the movements of a market in retreat. They are the movements of one relocating.

The tablets that disappeared from Elyxr and from 7oh.com did not stop existing. Archived copies of both storefronts show the same two products — a 500mg ten-count and a 1000mg twenty-count — listed and in stock, at Elyxr in late May and on 7oh.com in a buy-two-get-one promotion in early July. Today those same two products are sold directly by the brand itself, from its own store, alongside a display case, a master case, and a pallet tier of ten thousand units. The brand appears to have withdrawn from third-party retail and gone direct.

That shift carries a consequence worth stating plainly. The retailers that dropped the product are long-established sites with a decade or more of archival history, payment processors, and the ordinary visibility of consumer commerce. Several of the vendors now selling most aggressively have no archival history whatsoever: a check of the Internet Archive found no snapshot of two of the busiest current storefronts, at any address, at any point. A supply chain that moves from indexed, archived, processor-dependent retailers to unindexed direct sellers does not thereby become smaller. It becomes harder to see.

What none of these vendors mentions, anywhere, is a patent. This publication searched every page it retrieved — homepages, product pages, terms, FAQs and disclaimers across all thirteen storefronts, live and archived — for any reference to patent rights, infringement, licensing, cease and desist demands, or the patent holder. There were no such references. Neither, for that matter, was there any reference to the DEA, to Schedule I, or to the Federal Register. Whatever is driving this reshuffle, no vendor is explaining it to its customers at all.

The pattern extends past SR-17018. Retailers selling 7-OH have introduced products marketed as legal successors to it — one sells a mitragynine pseudoindoxyl product and another based on MGM-15, describing them under a "7-OH alternatives" heading and, in a February post, as "The Legal 7-OH Alternative."

Both of those compounds are named in the DEA's companion notice of intent, published July 6 alongside the 7-OH proposal, which covers mitragynine pseudoindoxyl, MGM-15 and MGM-16. They are proposed for the same schedule, on the same timeline, as the product they are being sold to replace. Fox 13 Tampa reported in July that a Hernando County man, Michael Walker, died after ingesting MGM-15 along with other synthetic kratom compounds.

At least one vendor has been candid about the cycle. In an August 4 post, a retailer acknowledged that "we sell pseudoindoxyl and MGM-15 products ourselves" and explained that it is now steering customers toward mitragynine because "mitragynine is not named in either notice." Another told customers that its current products "will remain available while we continue developing new compounds, alkaloids, and products."

Why This Matters Now

The federal 7-OH order has not yet issued, but supply has already contracted. State prohibitions have taken effect, retailers have cleared inventory, and online sellers have run closeout promotions ahead of the expected order. People who were taking those products daily are encountering that contraction now, and searching for something to take instead.

That is the market SR-17 vendors are addressing. The compound arrives with a plausible scientific pedigree — a real patent, a real laboratory of origin, real published papers — attached to claims those papers do not support.

Search data suggests the pitch is landing. US search volume for "sr-17018" has risen roughly ninefold since January 2025, from a few hundred queries a month to several thousand, and now runs at roughly twice the volume of searches for "7-oh withdrawal." More people are looking up the experimental compound than are looking for help getting off the one they are already taking.

At least one clinician has addressed the compound directly for a general audience. Writing in June, Harold Pierre, a board-certified addiction medicine physician, reviewed the evidence and noted that the early G-protein-biased account of how it works turned out to be more complicated than first believed. His conclusion for readers considering it was unambiguous: don't try SR-17018 until it receives FDA approval.

The Kratom Council takes no position on the pharmacology beyond reporting what the primary sources state, and has not independently tested any product. Readers weighing decisions about opioid dependence should be doing so with a clinician rather than a vendor. The SAMHSA National Helpline, at 1-800-662-HELP (4357), is free, confidential, and staffed around the clock, and findtreatment.gov lists licensed treatment providers by location.

Sources:

1. US Patent 10,751,335 B2 — "Signaling-biased mu opioid receptor agonists," inventors Bannister, Bohn and Schmid; assignment record showing The Scripps Research Institute and University of Florida Research Foundation, Inc.
2. Federal Register — "Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I," DEA notice of intent, document 2026-13364 (published July 1, 2026). Federal Register searched August 6, 2026; no subsequent order located.
3. Federal Register — "Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I," DEA notice of intent, document 2026-13581 (published July 6, 2026)
4. Center for Forensic Science Research and Education — monograph on 5,6-dichloro desmethylchlorphine
5. Fox 13 Tampa — "Lethal loophole: manufacturers of kratom compounds and the Florida ban" (July 29, 2026)
6. Cayman Chemical — SR-17018 product entry, CAS 2134602-45-0, including conditioned place preference data
7. Kudla L, et al. "Functional characterization of a novel opioid, PZM21, and its effects on the behavioural responses to morphine." (SR agonists: reward-associated behavior and physical dependence) — PMID 35056950
8. Pantouli F, et al. Tolerance to SR-17018 in the tail-immersion assay — PMID 33345829
9. Grim TW, et al. SR-17018 reverses morphine tolerance and suppresses morphine withdrawal in mice — PMID 31443104
10. Hill R, et al. Respiratory depression by oliceridine, tianeptine and SR-17018 in male mice — PMID 37489013
11. Gillis A, et al. Low intrinsic efficacy and "apparent bias" at the mu-opioid receptor — PMID 32234959
12. Singleton S, et al. Non-orthosteric engagement of the mu-opioid receptor by SR-17018 — PMID 39067665
13. The Herbert Wertheim UF Scripps Institute — Laura Bohn faculty pages
14. ClinicalTrials.gov — search for "SR-17018" returns zero registered studies (searched August 6, 2026)
15. Vendor marketing quotations were taken from the public pages of sr17direct.com, sr17018labs.com, simplereset.com, reset4good.com, burmanshealthshop.com, 7oh.com, realbotanicals.com, favordalkz.com and rawmit.com, all accessed August 6, 2026. The Kratom Council does not link to vendors of unapproved compounds; the citations are given so the claims can be independently checked.
16. Search-volume figures are from Ahrefs US keyword data, retrieved August 6, 2026.